The place of secondary complete cytoreductive surgery in advanced ovarian cancer

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.10.3322/caac.21442Search in Google Scholar

[2] Ovarian Cancer Staging. 2013 May 21 [cited 2013 Sep 9]. Available from: http://emedicine.medscape.com/article/2007140-overview.Search in Google Scholar

[3] Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10.10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-SSearch in Google Scholar

[4] Classe JM, Guyon F, Falandry C, Devouassoux-Shisheboran M, Selle F, Joly F. Cancer de l’ovaire; prise en charge pluridisciplinaire du cancer de l’ovaire en première ligne (Ovarian cancer; multidisciplinary management of ovarian cancer in first line treatment): Recommandation Saint Paul de Vence 2016. Bull Cancer. 2017;104(Suppl 1):S6–15.10.1016/S0007-4551(17)30157-1Search in Google Scholar

[5] Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.10.1200/JCO.2002.20.5.1248Search in Google Scholar

[6] Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.10.1016/j.ygyno.2009.03.018Search in Google Scholar

[7] Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschan Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44.10.1002/cncr.24149Search in Google Scholar

[8] Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;CD007565. doi: 10.1002/14651858.CD007565.pub2.doi: 10.1002/14651858.CD007565.pub2Search in Google Scholar

[9] Bacon M, Kitchener H, Stuart GC, Vermorken JB, Gynecologic Cancer InterGroup and participants of 4th Ovarian Cancer Consensus Conference. The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer. Int J Gynecol Cancer. 2011;21:746–9.10.1097/IGC.0b013e31821bb446Search in Google Scholar

[10] Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–8.10.1097/01.ogx.0000452705.82050.e4Search in Google Scholar

[11] Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32:1309–16.10.1200/JCO.2013.51.4240Search in Google Scholar

[12] Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019 May 2; pii: ijgc-2019-000308. doi: 10.1136/ijgc-2019-000308.10.1136/ijgc-2019-000308Search in Google Scholar PubMed

[13] Guo N, Peng Z. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study. J Ovarian Res. 2017;10:14.10.1186/s13048-017-0310-ySearch in Google Scholar PubMed PubMed Central

[14] Yang ZJ, Zhao BB, Li L. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. J Ovarian Res. 2016;9(1):57.10.1186/s13048-016-0266-3Search in Google Scholar PubMed PubMed Central

[15] Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer. 2009;115:1395–403.10.1002/cncr.24152Search in Google Scholar PubMed PubMed Central

[16] Catégorisation des rechutes du cancer de l’ovaire en fonction de l’intervalle libre sans platine (PFI), 4^ème conférence de consensus sur les cancers de l’ovaire (Vancouver 2010).Search in Google Scholar

[17] Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559–64.10.1016/j.ygyno.2006.03.051Search in Google Scholar PubMed

[18] Chéreau E, Ballester M, Lesieur B, Selle F, Coutant C, Rouzier R, et al. Complications de la chirurgie radicale des cancers de l’ovaire de stade avancé. Gynécologie Obstétrique Fertil. 2011;39:21–7.10.1016/j.gyobfe.2010.08.017Search in Google Scholar PubMed

[19] Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44.10.1002/cncr.24149Search in Google Scholar PubMed

[20] Zivanovic O, Aldini A, Carlson JW, Chi DS. Advanced cytoreductive surgery: American perspective. Gynecol Oncol. 2009;114(2 Suppl):S3–9.10.1016/j.ygyno.2008.11.033Search in Google Scholar PubMed

[21] Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650–4.10.1016/j.ygyno.2004.01.029Search in Google Scholar PubMed

[22] Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105:890–6.10.1038/bjc.2011.328Search in Google Scholar PubMed PubMed Central

[23] Petrillo M, Fagotti A, Farrandina G, Fanfani F, Constantini B. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol. 2013;131:36–41.10.1016/j.ygyno.2013.06.020Search in Google Scholar PubMed

[24] Legge F, Petrillo M, Adamo V, Pisconti S, Scambia G, Ferrandina G. Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. BMC Cancer. 2008;8:367.10.1186/1471-2407-8-367Search in Google Scholar PubMed PubMed Central

[25] Uzan C, Morice P, Rey A, Pautier P, Camatte S. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol. 2004;11:658–64.10.1245/ASO.2004.11.023Search in Google Scholar PubMed

[26] Amate P, Huchon C, Dessapt AL, Bensaid C, Medioni J, Le Frère Belda MA, et al. Ovarian cancer: sites of recurrence. Int J Gynecol Cancer. 2013;23:1590–6.10.1097/IGC.0000000000000007Search in Google Scholar PubMed

[27] Paik ES, Paik ES, Lee YY, Shim M, Choi HJ, Kim TJ, et al. Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. Aust N Z J Obstet Gynaecol. 2016;56:639–47.10.1111/ajo.12529Search in Google Scholar PubMed

[28] Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006;100:33–7.10.1016/j.ygyno.2005.07.123Search in Google Scholar PubMed

[29] Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E. Prognostic factors and clinical outcome of patients with recurrent early stage epithelial ovarian cancer: an Italian multicenter retrospective study. Int J Gynecol Cancer. 2013;23:461–8.10.1097/IGC.0b013e318286665bSearch in Google Scholar PubMed

[30] Giudice MT, D’Indinosante M, Cappuccio S, Gallotta V, Fagotti A, Scambia G, et al. Secondary cytoreduction in ovarian cancer: who really benefits? Arch Gynecol Obstet. 2018;298:873–9.10.1007/s00404-018-4915-1Search in Google Scholar PubMed

[31] Lee CK, Lord S, Grunewald T, Gebski V, Hardy-Bessard AC, Sehouli J, et al. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. Gynecol Oncol. 2015;136:18–24.10.1016/j.ygyno.2014.09.017Search in Google Scholar PubMed

[32] Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019;30:672–705.Search in Google Scholar

[33] Bogani G, Leone Roberti Maggiore U, Chiappa V, Ditto A, Martinelli F, Sabatucci I, et al. The addition of lymphadenectomy to secondary cytoreductive surgery in comparison with bulky node resection in patients with recurrent ovarian cancer. Int J Gynaecol Obstet. 2018;143:319–24.10.1002/ijgo.12667Search in Google Scholar PubMed

[34] Wang M, Zhou J, Zhang L, Zhao Y, Zhang N, Wang L, et al. Surgical treatment of ovarian cancer liver metastasis. Hepatobiliary Surg Nutr. 2019;8:129–37.10.21037/hbsn.2018.12.06Search in Google Scholar PubMed PubMed Central

[35] Van Driel WJ, Koole SN, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:1363–4.10.1056/NEJMoa1708618Search in Google Scholar PubMed

[36] Hotouras A, Desai D, Bhan C. Heated intra peritoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. J Gynecol Cancer. 2016;26:661–70.10.1097/IGC.0000000000000664Search in Google Scholar PubMed

[37] Cianci S, Ronsini C, Vizzielli G, Tropea A, Biondi A, Scambia G, et al. Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence. Updates Surg. 2019;71:389–94.10.1007/s13304-018-0600-ySearch in Google Scholar PubMed

[38] Escobar PF, Levinson KL, Magrina J, Martino MA, Barakat RR, Fader AN, et al. Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: a multi-institutional study. Gynecol Oncol. 2014;134:253–6.10.1016/j.ygyno.2014.05.007Search in Google Scholar PubMed

[39] Magrina JF, Cetta RL, Chang YH, Guevara G, Magtibay PM. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol. 2013;129:336–40.10.1016/j.ygyno.2013.01.015Search in Google Scholar PubMed

[40] Holloway RW, Brudie LA, Rakowski JA, Ahmad S. Robotic-assisted resection of liver and diaphragm recurrent ovarian carcinoma: description of technique. Gynecol Oncol. 2011;120:419–22.10.1016/j.ygyno.2010.09.007Search in Google Scholar PubMed

[41] Nezhat FR, Pejovic T, Finger TN, Khalil SS. Role of minimally invasive surgery in ovarian cancer. J Minim Invasive Gynecol. 2013;20:754–65.10.1016/j.jmig.2013.04.027Search in Google Scholar PubMed